All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F21%3AE0109039" target="_blank" >RIV/00843989:_____/21:E0109039 - isvavai.cz</a>

  • Result on the web

    <a href="https://advances.sciencemag.org/content/advances/7/24/eabf1526.full.pdf" target="_blank" >https://advances.sciencemag.org/content/advances/7/24/eabf1526.full.pdf</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1126/sciadv.abf1526" target="_blank" >10.1126/sciadv.abf1526</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Development of next-generation tumor-homing induced neural stem cells to enhance treatment of metastatic cancers

  • Original language description

    Engineered tumor-homing neural stem cells (NSCs) have shown promise in treating cancer. Recently, we transdifferentiated skin fibroblasts into human-induced NSCs (hiNSC) as personalized NSC drug carriers. Here, using a SOX2 and spheroidal culture-based reprogramming strategy, we generated a new hiNSC variant, hiNeuroS, that was genetically distinct from fibroblasts and first-generation hiNSCs and had significantly enhanced tumor-homing and antitumor properties. In vitro, hiNeuroSs demonstrated superior migration to human triple-negative breast cancer (TNBC) cells and in vivo rapidly homed to TNBC tumor foci following intracerebroventricular (ICV) infusion. In TNBC parenchymal metastasis models, ICV infusion of hiNeuroSs secreting the proapoptotic agent TRAIL (hiNeuroS-TRAIL) significantly reduced tumor burden and extended median survival. In models of TNBC leptomeningeal carcinomatosis, ICV dosing of hiNeuroS-TRAIL therapy significantly delayed the onset of tumor formation and extended survival when administered as a prophylactic treatment, as well as reduced tumor volume while prolonging survival when delivered as established tumor therapy.

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database

  • CEP classification

  • OECD FORD branch

    30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)

Result continuities

  • Project

  • Continuities

    V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Others

  • Publication year

    2021

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Science Advances

  • ISSN

    2375-2548

  • e-ISSN

    2375-2548

  • Volume of the periodical

    7

  • Issue of the periodical within the volume

    eabf1526)

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    14

  • Pages from-to

    1-14

  • UT code for WoS article

    000659923500020

  • EID of the result in the Scopus database

    2-s2.0-85107471404